Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22654904 | 0.82 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL22654902 | 0.82 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL22654906 | 0.82 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL3070688 | 0.80 | PREP (0.53) | NPSR1PREPTSHRL3MBTL1KDM4E | |
| SCHEMBL3070684 | 0.80 | PREP (0.53) | NPSR1PREPTSHRL3MBTL1KDM4E | |
| SCHEMBL3070690 | 0.80 | PREP (0.53) | NPSR1PREPTSHRL3MBTL1KDM4E | |
| SCHEMBL13434443 | 0.78 | ACE2 (0.55) | NPSR1PREPTSHRL3MBTL1KDM4E | |
| SCHEMBL13434440 | 0.78 | ACE2 (0.55) | NPSR1PREPTSHRL3MBTL1KDM4E | |
| SCHEMBL13631108 | 0.78 | ACE2 (0.55) | NPSR1PREPTSHRL3MBTL1KDM4E | |
| SCHEMBL16789713 | 0.77 | PREP (0.49) | NPSR1PREPTSHRL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-11-12 | — | — | US | disclosed |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2022-08-11 | — | — | US | disclosed |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | NPSR1 1056/4885PREP 1221/4885TSHR 2465/4885 |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | NPSR1 1056/4885PREP 1221/4885TSHR 2465/4885 |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | NPSR1 1056/4885PREP 1221/4885TSHR 2465/4885 |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | NPSR1 1056/4885PREP 1221/4885TSHR 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.